Physician profile
Margaret Rinker
NPI 1609840487
$3,381.07
in general payments reported to CMS, 2019-2025
23 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2021: $244 · 2022: $363 · 2023: $730 · 2024: $694 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,371 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,370.66 |
| Education | $136.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $650.47 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $618.75 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Galderma Laboratories, L.P. | $327.13 | 2019-2025 | Oracea, Nemluvio |
| Sun Pharmaceutical Industries INC. | $322.66 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Genzyme Corporation | $175.75 | 2022-2025 | |
| Abbvie INC. | $173.35 | 2023-2025 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $165.97 | 2022-2025 | Libtayo, Dupixent |
| Journey Medical Corporation | $158.53 | 2021-2022 | |
| Allergan, INC. | $136.35 | 2019 | |
| Revance Therapeutics, INC. | $98.95 | 2024 | Daxxify |
| Pfizer INC. | $90.21 | 2021-2025 | |
| Ucb, INC. | $79.38 | 2025 | Bimzelx |
| Amgen INC. | $79.18 | 2022-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $67.69 | 2024-2025 | |
| Almirall LLC | $67.21 | 2022-2025 | Seysara |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $26.13 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $24.56 | 2021 | |
| Mayne Pharma Commercial LLC | $24.09 | 2025 | |
| Verrica Pharmaceuticals INC. | $24.06 | 2025 | Ycanth |
| Incyte Corporation | $21.30 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.33 | 2024 | Sotyktu |
| Lilly USA, LLC | $16.51 | 2025 | Ebglyss, Taltz |
| Paratek Pharmaceuticals, INC. | $13.51 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Rinker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.